We suggest against the routine use of additional risk markers (e.g., high-sensitivity C-reactive protein, ankle-brachial index, coronary artery calcium) when assessing cardiovascular risk. Weak against [26,29,32-35] Weak against Reviewed, New- replaced 6. For primary prevention, we recommend offering a moderate- dose statin in patients with a >12% 10-year cardiovascular risk or low-density lipoprotein cholesterol >190 mg/dL or diabetes. Weak for, Weak for, Strong for Additional references: Strong for Reviewed, New- replaced a Evidence column: The first set of references listed in each row in the evidence column constitutes the evidence base for the recommendation. To be included in the evidence base for a recommendation, a reference needed to be identified through the 2019 evidence review or included in the evidence base for the 2014 VA/DoD Dyslipidemia CPG. The second set of references in the evidence column ( Additional References ) includes references that provide additional information related to the recommendation but which were not systematically identified through a literature review. These references were not included in the evidence base for the recommendation and, therefore, did not influence the strength and direction of the recommendation. b 2020 Strength of Recommendation column: Refer to the Grading Recommendations section for more information on how the strength of the recommendation was determined using GRADE methodology. c Recommendation Category column: Refer to the Recommendation Categorization section for more information on the description of the categorization process and the definition of each category. Recommendation 2014 Strength of Recommendation Evidence 2020 Strength of Recommendation Recommendation Category 7. For primary prevention, we suggest offering a moderate-dose statin for patients with a 10-year cardiovascular risk between 6% and 12% following a discussion of risks, limited benefit, and an exploration of the patient s values and preferences. Weak for, Strong for Additional references: Weak for Reviewed, New- replaced 8. 